---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021505"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:39:29.423147+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial

## Summary
- Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.
- INB-100 Phase 1: 100% complete remissions in 7 evaluable leukemia patients; all alive; selected RP2D.
- FDA orphan drug designation for INB-400 and INB-410 for malignant gliomas, including GBM.
- INB-200 Phase 1 data selected for oral abstract at ASCO 2023; new preclinical data in ovarian cancer.

## SEC filing metadata
- accession: 0000950170-23-021505
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/0000950170-23-021505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/inab-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021505
- JSON: https://secwatch.observer/filing/0000950170-23-021505.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021505.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported first quarter ended March 31, 2023 results: net income $7.5 million, EPS $0.30 per basic and diluted common share.
  - Period: first quarter ended March 31, 2023
  - Net income: $7.5 million
  - EPS: $0.30 per basic and diluted common share
  - Result: reported results
  source text: The Company reported a net loss of $7.5 million, or $0.30 per basic and diluted common share, for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/0000950170-23-021505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.